PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Stephen J Freedland Selected Research
Obesity
09/2008
Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database.
09/2008
Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
11/2007
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
05/2007
Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
02/2006
Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection.
11/2005
Obesity and capsular incision at the time of open retropubic radical prostatectomy.
09/2005
Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center.
06/2005
Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy.
04/2005
Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years.
08/2004
Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins.
02/2004
Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group.
Articles by Research Topic
Disease
23
Prostatic Neoplasms (Prostate Cancer)
09/2008 - 04/2003
11
Obesity
09/2008 - 02/2004
7
Neoplasms (Cancer)
08/2008 - 02/2002
1
Carcinoma (Carcinomatosis)
12/2003
1
Pain (Aches)
06/2003
1
Renal Cell Carcinoma (Grawitz Tumor)
01/2003
Drug/Important Bio-Agent (IBA)
11
Prostate-Specific Antigen (Semenogelase)
IBA
09/2008 - 02/2002
1
Insulin (Novolin)
FDA Link
01/2008
1
Cyclooxygenase 2 (Cyclooxygenase-2)
IBA
08/2006
1
Dinoprostone (PGE2)
FDA Link
08/2006
1
Hormones
IBA
06/2003
1
Neprilysin (Neutral Endopeptidase)
IBA
04/2003
Therapy/Procedure
27
Prostatectomy (Retropubic Prostatectomy)
09/2008 - 02/2002
2
Nephrectomy
06/2003 - 01/2003
1
Chemoprevention
05/2008
1
Hemodilution
11/2007
1
Drug Therapy (Chemotherapy)
01/2005
1
Fat-Restricted Diet (Diet, Fat Restricted)
02/2004
1
Heterologous Transplantation (Xenotransplantation)
02/2004
1
Lymph Node Excision (Lymph Node Dissection)
01/2003